Advik Laboratories Limited (ADVIKLA) Share Price
BSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE537C01019
Key metrics
- Market Cap
- ₹4 Cr
- P/E Ratio
- —
- EPS
- -0.53
- Book Value
- 0.04
- P/B Ratio
- 49.75
- ROE
- -1,489.05%
- ROCE
- -12.37%
- Debt / Equity
- 109.84
- Net Margin
- —
- Revenue Growth
- —
- Profit Growth
- -13.6%
- Dividend Yield
- —
- 52W High
- ₹2.08
- 52W Low
- ₹1.57
- Market Cap Band
- micro cap
- Face Value
- —
Ratios computed from the annual results period ending 2026-03-31.
About Advik Laboratories Limited
MPS Pharmaa Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. The company offers generic products, including antibacterials, antiallergics, antifungals, anthelminthics, antihypertensives, antimalarials, antituberculosis, corticosteroids, erectile dysfunction, gastrointestinal agents, sedatives, and others, as well as analgesic, antipyretic, and anti-inflammatory products. It also offers ethical products, such as Wibatol, Wibatol-O, Robial, Twosum, Majispa, Arfa Gel, Stibomin, and Chewfe-C. In addition, the company exports its products to East Asia, Southeast Asia, the Middle East, South America, and Africa. The company was formerly known as Advik Laboratories Limited and changed its name to MPS Pharmaa Limited in December 2022. MPS Pharmaa Limited was incorporated in 1994 and is based in New Delhi, India.
- Headquarters
- New Delhi, India
- Promoter Holding
- 69.93%
The full Advik Laboratories Limited analysis
Create a free account to open the complete ADVIKLA deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.